<DOC>
	<DOC>NCT00409201</DOC>
	<brief_summary>30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.</brief_summary>
	<brief_title>Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia</brief_title>
	<detailed_description>all participants will be administered panss, sans, esrs, calgary, progesterom, sexual functioning scale, ham-a, covy, hamilton depression scale, and cgi and cgi improved rating on the first visit, as well as blood tests, ecg and weight. they will then be tested using a computer cognitive test (cogscan test) that lasts about 45 minutes. next, they will be given either a two week dose of placebo or treatment (2 mg * 2 daily for first week, then 4 mg. day, 2 mg. night for the second week). after two weeks they the dose is increased to 4 mg. * 2 daily. at four weeks all tests are readministered, as well as at six weeks. the study is concluded at 6 weeks, following a readministration of tests. physical examination is also administered at the conclusion.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>schizophrenia all types 18&gt; uti &gt;65 non organic state no depression treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>reboxetine</keyword>
	<keyword>cognitive</keyword>
	<keyword>behavior</keyword>
</DOC>